Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 5:01 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 241–264 of 1,099 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Healthy Control Subjects Clear all

Conditions: Mydriasis, Dilation
Interventions: Phentolamine Ophthalmic Solution 0.75%, Phentolamine Ophthalmic Solution Vehicle; Drug
Lead sponsor: Opus Genetics, Inc; Industry
Eligibility: 12 Years and older
Enrollment: 368 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 15
States / cities: Newport Beach, California • Westminster, California • Delray Beach, Florida + 12 more

Conditions: Type 1 Diabetes
Interventions: Measurement of vascular function per SphymgnoCor equipment; Procedure
Lead sponsor: Children's Mercy Hospital Kansas City; Other
Eligibility: 12 Years to 14 Years
Enrollment: 85 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2007
U.S. locations: 1
States / cities: Kansas City, Missouri

Conditions: Healthy
Interventions: clopidogrel, Placebo, omeprazole; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: Bridgewater, New Jersey

Conditions: Healthy
Interventions: VBY-891, Placebo; Drug
Lead sponsor: Virobay Inc.; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 89 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: Evansville, Indiana

Conditions: Schizophrenia
Interventions: APN1125, Placebo; Drug
Lead sponsor: CoMentis; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 58 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Glendale, California

Conditions: Healthy Volunteers
Interventions: MGTA-145, plerixafor, Placebo; Biological
Lead sponsor: Ensoma; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 107 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Cognitive Deficit
Interventions: Brain Stimulation; Procedure
Lead sponsor: University of Cincinnati; Other
Eligibility: 18 Years to 70 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Healthy
Interventions: BMS-963272, Placebo; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 88 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Healthy Volunteer
Interventions: RO4917523, placebo; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 42 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 1
States / cities: New York, New York

Conditions: Meningitis, Meningococcal
Interventions: rLP2086 vaccine, control; Biological
Lead sponsor: Pfizer; Industry
Eligibility: 10 Years to 25 Years
Enrollment: 5,715 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2014
U.S. locations: 39
States / cities: Huntsville, Alabama • Chandler, Arizona • Tempe, Arizona + 28 more

Conditions: Pulmonary Arterial Hypertension
Interventions: L606 (Liposomal Treprostinil) Inhalation Solution 51ug, L606 Inhalation System, Placebo Solution; Drug · Device · Other
Lead sponsor: Pharmosa Biopharm Inc.; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 52 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Influenza
Interventions: AVI-7100 versus placebo; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 60 Years
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Type 2 Diabetes Mellitus
Interventions: TAK-648, Placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 2
States / cities: Anaheim, California • Chula Vista, California

Conditions: Schizophrenia
Interventions: ITI-214 Dose A, ITI-214 Dose B, ITI-214 Dose C, ITI-214 Dose D (Elderly), Placebo, ITI-214 Dose E, ITI-214 Dose F, ITI-214 Dose G, ITI-214 Dose H; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years and older
Enrollment: 76 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 2
States / cities: Glendale, California • New York, New York

Conditions: Alopecia, Androgenetic
Interventions: TDM-105795, Placebo; Drug
Lead sponsor: Technoderma Medicines Inc.; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 2
States / cities: San Diego, California • College Station, Texas

Conditions: Diabetes
Interventions: HTI-2088, Placebo; Drug
Lead sponsor: Hengrui Therapeutics, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Influenza A Virus, H1N1 Subtype
Interventions: Zanamivir; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Healthy
Interventions: Entolimod, Placebo, Influenza vaccine; Drug
Lead sponsor: Robert J. Pignolo; Other
Eligibility: 65 Years and older
Enrollment: 61 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Healthy Subjects, Pharmacokinetics of ASP015K
Interventions: ASP015K, Placebo; Drug
Lead sponsor: Astellas Pharma Inc; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008
U.S. locations: 2
States / cities: Miami, Florida • Saint Paul, Minnesota

Conditions: Thrombosis
Interventions: BMS-986141, Placebo, Aspirin, Itraconazole; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 148 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 2
States / cities: Cypress, California • Austin, Texas

Conditions: Healthy
Interventions: MOA-728; Drug
Lead sponsor: Bausch Health Americas, Inc.; Industry
Eligibility: 18 Years to 50 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Healthy
Interventions: HEPLISAV and/or Placebo, Engerix-B; Biological
Lead sponsor: Dynavax Technologies Corporation; Industry
Eligibility: 40 Years to 70 Years
Enrollment: 2,452 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 29
States / cities: Huntsville, Alabama • San Diego, California • Santa Ana, California + 26 more

Conditions: Bacterial Infections
Interventions: QPX7728, Placebo, QPX2014; Drug
Lead sponsor: Qpex Biopharma, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 82 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Cypress, California

Conditions: Healthy
Interventions: PF-06260414, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 21 Years to 50 Years · Male only
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: New Haven, Connecticut

Search by objective public record fields.

Safety and Efficacy of Nyxol (0.75% Phentolamine Ophthalmic Solution) to Reverse Pharmacologically-Induced Mydriasis (MIRA-3)

Vascular Function in Adolescent, Diabetic Children

Interaction Study of Clopidogrel 300/75 mg Given Alone or With Omeprazole 80 mg 12 Hours Apart in Healthy Subjects

Safety Study of VBY-891 in Healthy Volunteers After Single or Multiple (7 Days) of Oral Dosing (VBY891P1)

Safety, Tolerability, and Pharmacokinetics of Single Doses of APN1125 in Healthy Normal Subjects

Study Assessing Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MGTA-145 in Healthy Volunteers as a Single Agent or in Combination With Plerixafor

Studying the Effects of Brain Stimulation on Cognitive Control and Associated EEG in Human Subjects.

Randomized, Placebo-Controlled, Double-Blind, Ascending Single and Multiple Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of BMS-963272 in Healthy Subjects

A Pharmacokinetic Study of RO4917523 in Healthy Japanese and Caucasian Subjects

A Global Phase 3 Safety Study of 120 mcg rLP2086 Vaccine in Adolescents and Young Adults Aged 10 to 25 Years

Single Ascending Dose Study for Evaluation of Safety, Tolerability and Pharmacokinetics of L606

Testing the AVI-7100 Flu Drug in Healthy Volunteers

TAK-648 Multiple-Rising Dose Study in Healthy Japanese Participants and Non-Japanese Participants With Type 2 Diabetes Mellitus

Safety and Tolerability of Multiple Doses of ITI-214 in Healthy Adults and in Adults With Stable Schizophrenia

A Phase 1 Study of TDM-105795 Topical Solution in Male Subjects With Androgenetic Alopecia (AGA)

A Phase 1, Study to Evaluate HTI-2088 Tablet

Crossover Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Repeat Dose Zanamivir/Placebo Via Devices Administered Twice Daily for 5 Days

Entolimod on Immunosenescence in Healthy Geriatric Subjects Receiving Influenza Vaccination

A Study to Assess the Safety, Tolerability and Pharmacokinetics of ASP015K

Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BMS-986141 in Healthy Subjects

Study Evaluating the Effects of MOA-728 on Cardiac Repolarization in Healthy Subjects

Safety and Immunogenicity Study of the Hepatitis B Virus (HBV) Vaccine, HEPLISAV Compared to Engerix-B Vaccine

P1 Single and Multiple Ascending Dose (SAD/MAD) Study of IV QPX7728 Alone and Combined With QPX2014 in NHV

Study To Evaluate Safety And Tolerability Of Single And Multiple Ascending Doses Of PF- 06260414 In Healthy Western And Japanese Male Subjects